Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis
Rituximab is an effective treatment of rheumatoid arthritis (RA), which has been approved for the treatment of moderate to severe disease in patients with an inadequate response to anti-TNF therapies. Rituximab differs from other available biological agents for RA by way of its unique mode of acti...
| 發表在: | Swiss Medical Weekly |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Article |
| 語言: | 英语 |
| 出版: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2010-07-01
|
| 主題: | |
| 在線閱讀: | https://www.smw.ch/index.php/smw/article/view/1150 |